logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

BRAF+ melanoma: first-line anti-PD-1 therapy tops MAPK inhibitors for OS

Multicenter analysis fills the gaps left by lack of head-to-head trials.